Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 3, 28 April 2023
Open
Access | Article
Review of Treatments for ADPKD on Tolvaptan and ketogenic Dietary Intervention as a Novel Therapy
* Author to whom correspondence should be addressed.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent genetic kidney disease, affected millions of individuals worldwide. And it is also one of the most prevalent causes of kidney failures and transplants. Previously, in many years, mitigating its symptoms had been the only treatment for this disease. After more than a decade after the early clinical studies of medicines for ADPKD began, the first medication that may successfully delay the course of the condition is now on the market. Due to the severe side effects and high cost of tolvaptan, it cannot be considered a full success, but rather the beginning of therapeutic research. More recently, enlightened by the discovery of the defective metabolism of PKD related cells, researchers have been designing dietary plans and new lifestyles for ADPKD patients to slow down or even halt the disease progression. Current outcomes have been promising. This article will address the best practices for treating ADPKD patients, with a focus on medications that have been proved to be beneficial in preserving kidney’s function and structure.
Keywords
treatment, tolvaptan, ketogenic diet, autosomal dominant polycystic kidney disease, metabolism
References
1. M.B. Lanktree, A. Haghighi, E. Guiard, I.-A. Iliuta, X. Song, P.C. Harris, A.D. Paterson, and Y. Pei, Journal of the American Society of Nephrology 29, 2593 (2018)
2. S. Strubl, S. Oehm, J.A. Torres, F. Grundmann, J. Haratani, M. Decker, S. Vuong, A. Kaur Bhandal, N. Methot, R. Haynie-Cion, F. Meyer, F. Siedek, U. Korst, R.-U. Mü, and T. Weimbs, Clinical Kidney Journal (2021).
3. A.S.L. Yu, C. Shen, D.P. Landsittel, J.J. Grantham, L.T. Cook, V.E. Torres, A.B. Chapman, K.T. Bae, M. Mrug, P.C. Harris, F.F. Rahbari-Oskoui, T. Shi, and W.M. Bennett, Kidney International 95, 1253 (2019).
4. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, E. Higashihara, R.D. Perrone, H.B. Krasa, J. Ouyang, and F.S. Czerwiec, New England Journal of Medicine 367, 2407 (2012).
5. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, R.D. Perrone, G. Koch, J. Ouyang, R.D. McQuade, J.D. Blais, F.S. Czerwiec, and O. Sergeyeva, New England Journal of Medicine 377, 1930 (2017).
6. L.F. Menezes, C.-C. Lin, F. Zhou, and G.G. Germino, EBioMedicine 5, 183 (2016).
7. R.-U. Müller and T. Benzing, Clinical Kidney Journal 11, 2 (2018).
8. J.A. Torres, M. Rezaei, C. Broderick, L. Lin, X. Wang, B. Hoppe, B.D. Cowley, V. Savica, V.E. Torres, S. Khan, R.P. Holmes, M. Mrug, and T. Weimbs, Journal of Clinical Investigation 129, 4506 (2019).
9. D.M. Bruen, J.J. Kingaard, M. Munits, C.S. Paimanta, J.A. Torres, J. Saville, and T. Weimbs, Kidney and Dialysis 2, 183 (2022).
10. M. Bargagli, N.A. Dhayat, M. Anderegg, M. Semmo, U. Huynh-Do, B. Vogt, P.M. Ferraro, and D.G. Fuster, Clinical Journal of the American Society of Nephrology 15, 1007 (2020).
11. T.R. Tidwell, K. Søreide, and H.R. Hagland, Aging and Disease 8, 662 (2017).
12. B. Reed, I. Helal, K. McFann, W. Wang, X.-D. Yan, and R.W. Schrier, Nephrology Dialysis Transplantation 27, 2862 (2011).
13. K.L. Nowak and K. Hopp, Clinical Journal of the American Society of Nephrology 15, 577 (2020).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
- ISBN (Print)
- 978-1-915371-25-6
- ISBN (Online)
- 978-1-915371-26-3
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/3/20220214
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited